Rockefeller Capital Management L.P. Buys 5,526 Shares of Novartis AG $NVS

Rockefeller Capital Management L.P. boosted its stake in shares of Novartis AG (NYSE:NVS) by 5.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 108,205 shares of the company’s stock after buying an additional 5,526 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Novartis were worth $14,918,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. World Investment Advisors lifted its position in shares of Novartis by 12.9% during the 4th quarter. World Investment Advisors now owns 50,214 shares of the company’s stock valued at $6,923,000 after buying an additional 5,719 shares in the last quarter. Nalls Sherbakoff Group LLC purchased a new stake in Novartis in the 4th quarter worth approximately $34,000. Larry Mathis Financial Planning LLC bought a new stake in Novartis during the 4th quarter worth approximately $787,000. Corient Private Wealth LLC raised its stake in Novartis by 4.7% during the 4th quarter. Corient Private Wealth LLC now owns 479,904 shares of the company’s stock worth $66,203,000 after acquiring an additional 21,364 shares during the period. Finally, Auto Owners Insurance Co lifted its holdings in Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after purchasing an additional 4,594,726 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NVS. Weiss Ratings lowered shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Sanford C. Bernstein upgraded shares of Novartis to a “hold” rating in a research note on Thursday, March 19th. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Wednesday, March 11th. Finally, Morgan Stanley increased their price target on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $141.20.

Novartis Trading Up 3.0%

NVS stock opened at $153.42 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. Novartis AG has a 1-year low of $112.34 and a 1-year high of $170.46. The business has a 50 day simple moving average of $148.97 and a two-hundred day simple moving average of $149.16. The company has a market capitalization of $292.75 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 2.62 and a beta of 0.46.

Novartis (NYSE:NVS) last released its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The company had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. During the same quarter in the previous year, the business earned $2.28 EPS. The company’s quarterly revenue was down .9% on a year-over-year basis. Research analysts anticipate that Novartis AG will post 8.82 EPS for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.